Actively Recruiting
Open-Label Study of Ianalumab With Thrombopoietin Receptor Agonist in Adults With Primary Immune Thrombocytopenia or Evans Syndrome
Led by Novartis Pharmaceuticals · Updated on 2026-11-03
164
Participants Needed
20
Research Sites
84 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the tolerability of ianalumab combined with an investigators choice thrombopoietin receptor agonist IC TPO-RA in adults with primary immune thrombocytopenia ITP who have had between one and four prior treatments and have stable IC TPO-RA dosing. The study also includes an exploratory group with primary Evans syndrome ES where IC TPO-RA therapy is appropriate. This is a Phase 2, open-label trial focusing on treatment tolerability and safety. Participants receive ianalumab at a dose of 9 mgkg by infusion every 4 weeks for 16 weeks alongside their chosen IC TPO-RA, which is administered as per usual prescribing guidelines. The study includes a 28-day screening period to confirm eligibility, followed by the 16-week treatment phase. After treatment, there is a 16-week tapering period for the IC TPO-RA, and then all participants enter a long-term safety follow-up lasting 60 weeks 15 months. During the study, participants undergo regular monitoring of platelet counts and adverse events to evaluate treatment tolerability. Researchers track platelet count changes and the success of tapering IC TPO-RA doses. Safety assessments will continue throughout the study, including the long-term follow-up period. Overall participation may last over two years, including screening, treatment, tapering, and safety monitoring.
CONDITIONS
Brief Title
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here